Clinical trials in 2025 will be beset by rising costs and uncertain regulations while also benefiting from new technologies ...
After a year that saw Ikena Oncology trim back its workforce and pipeline, the oncology biotech thinks it has found a ...
The year kicked off with a flurry of dealmaking at the J.P. Morgan Healthcare Conference in January, and the pace of news ...
Galectin's MASH treatment reduces varices but fails to hit statistical significance in phase 3 trial
Galectin Therapeutics’ stock has halved since the company revealed its investigational drug failed to significantly reduce ...
A deal with Shanghai Jemincare Pharmaceutical has filled the hole. Rapt is paying $35 million upfront, plus up to $672.5 ...
The FDA has granted a groundbreaking approval to Humacyte for its off-the-shelf, bioengineered blood vessel implant, designed ...
A phase 3 trial of Novo Nordisk’s next-generation obesity prospect CagriSema has failed to achieve the level of weight loss ...
The FDA has denied Zealand Pharma’s approval bid for glepaglutide—a possible challenger to Takeda’s Gattex—in short bowel ...
Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal ...
Phase 2 trial data will continue to be the name of the game when it comes to VC investments into biopharma in 2025, according ...
Bristol Myers Squibb has turned to the source of Leqembi to further its push into Alzheimer’s disease, paying BioArctic $100 ...
Flagship CEO-partner and Ring CEO Tuyen Ong, M.D., will also be shifting to an advisory role in the new year, according to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback